Press "Enter" to skip to content

Posts published in “News”

New Report Highlights Nuvectis Pharma’s NXP900’s Potential in NSCLC Treatment following Recent Developments from Summit Therapeutics

Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data, following recent developments announced by Summit Therapeutics (NASDAQ: SMMT)